By Kurt R. Karst — The FDA Reduction-in-Force (Termination)—or “RIF(T)”—announced last...
Category - News
More on the Impact of the FDA RIFs: How Information Disclosure...
By Sarah Wicks & Anne K. Walsh — The recent and drastic Reduction In Force (RIF) at the U. S...
Court Rejects Challenge to DEA ALJ Hearing Authority Over Removal Power
Déjà Vu: OPDP Again Targets Provider Branded Website of Accelerated Approval Drug in Second Untitled Letter of 2025
ASCA 2024 Performance Update: Can ASCA Improve Submission Predictability?
Enforcement Under the New FDA: HPM to Host a Q&A Webinar on FDC Act Enforcement with Three Former Federal Prosecutors
Bring Out Your Meds! To the Feds!
Where Does Rare Disease and Patient-Focus Fall into Commissioner Makary’s Priorities & the MAHA Platform for FDA? A New Ultrarare Approval Pathway & More
Reports Document FDA Review Delays: What Drugmakers Should Know Now